Maxim Group analyst Jason McCarthy downgrades Aridis Pharmaceuticals (NASDAQ:ARDS) from Buy to Hold.
GRAIL Presents New Data On Galleri And Its Methylation Platform At The Annual American Association For Cancer Research Meeting
New Data Will Highlight Use of GRAIL's Targeted Methylation Platform Across Early Cancer Detection and Precision OncologyLonger-term Data Underscore the Potential Value of GRAIL's Galleri® for Repeat Screening for
